Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Taipei Veterans General Hospital currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 6 distinct art units, indicating a diverse range of specialized subject matter within the life sciences sector. The presence of 7 distinct examiners suggests that each pending matter is being handled by a different individual, preventing any single examiner from having an outsized influence on the overall portfolio timeline.
ORTEGA, MARTIN NATHAN is identified as the busiest examiner for this entity, though they are only responsible for 1 pending office action. This highlights a prosecution landscape where no individual examiner manages more than one case. Practitioners should prepare for varied examination styles across the 7 active matters, as the lack of examiner overlap limits the ability to apply insights from one case to another within the hospital's current patent filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORTEGA, MARTIN NATHAN | 1 | 26.8% | +32.8% |
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
| PATEL, NEHA | 1 | 24.0% | +21.0% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| PARK, GRACE A | 1 | 76.3% | +17.6% |
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 13d |
| 19005976 | IDENTIFICATION AND PROGNOSIS SYSTEM, OPERATION METHOD THEREOF AND NON-TRANSITORY COMPUTER READABLE MEDIUM | ORTEGA, MARTIN NATHAN | — |
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18407238 | SPECIMEN TREATMENT METHOD | KASAYAN, KATRIEL BARCELLANO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 13d |
| 19005976 | IDENTIFICATION AND PROGNOSIS SYSTEM, OPERATION METHOD THEREOF AND NON-TRANSITORY COMPUTER READABLE MEDIUM | ORTEGA, MARTIN NATHAN | — |
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | — |
| 18515028 | NANOPARTICLES-MEDIATED CRISPR-CAS9 FOR GENE THERAPY | KONOPKA, CATHERINE ANNE | — |
| 18308625 | LEFT VENTRICULAR HYPERTROPHY PREDICTION MODEL TRAINING METHOD AND DEVICE THEREOF | PARK, GRACE A | — |
| 17924933 | COMPOSITIONS AND METHODS FOR TREATING SLC26A4-ASSOCIATED HEARING LOSS | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 3699 | 1 |
| 1634 | 1 |
| 4100 | 1 |
| 2144 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19005976 | IDENTIFICATION AND PROGNOSIS SYSTEM, OPERATION METHOD THEREOF AND NON-TRANSITORY COMPUTER READABLE MEDIUM | ORTEGA, MARTIN NATHAN | — | §101§102§103 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18690712 | SYNTHETIC COMPOUND, KIT COMPRISING THE SAME, AND USES THEREOF | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18584818 | SYSTEM AND METHOD FOR MANAGING MEDICAL QUALITY INDICATOR | PATEL, NEHA | 3699 | §101§102§103§112 | Non-Final OA | 13d | Pending | Feb 22, 2024 |
| 18407238 | SPECIMEN TREATMENT METHOD | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Final Rejection | — | Pending | Jan 08, 2024 |
| 18515028 | NANOPARTICLES-MEDIATED CRISPR-CAS9 FOR GENE THERAPY | KONOPKA, CATHERINE ANNE | 4100 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18308625 | LEFT VENTRICULAR HYPERTROPHY PREDICTION MODEL TRAINING METHOD AND DEVICE THEREOF | PARK, GRACE A | 2144 | §103 | Final Rejection | — | Pending | Apr 27, 2023 |
| 17924933 | COMPOSITIONS AND METHODS FOR TREATING SLC26A4-ASSOCIATED HEARING LOSS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Non-Final OA | — | Pending | Nov 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTaipei Veterans General Hospital has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Martin Nathan Ortega has the most, with 1 of Taipei Veterans General Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
